Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Validation of a sickle cell disease-specific iPSC platform as a preclinical screening tool

Braden Pate, Madeline Labott, Anna Goldstein et al. Nov 03, 2025 pp. 4706-4706 10.1182/blood-2025-4706

Abstract Sickle cell disease (SCD), caused by a mutation in the β-globin gene, renders hemoglobin prone to polymerization, resulting in anem...

The number of CD34 cells employed in autologous hematopoietic stem cell transplantation in persons with multiple sclerosis is unrelated to the neurological outcome of the procedure. experience in 1417 patients.

Michelle Lavoignet Cisneros, Olivia Lira Lara, Miguel Viveros Lugo et al. Nov 03, 2025 pp. 7617-7617 10.1182/blood-2025-7617

Abstract Background: Autologous hematopoietic stem cell transplantation (aHSCT) is widely employed in the treatment of persons with multiple...

Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies

Hsin-An Hou, Kenshi Suzuki, David Bin-Cha Wu et al. Nov 03, 2025 pp. 4574-4574 10.1182/blood-2025-4574

Abstract Introduction Improvement in disease treatment including access to novel agents such as anti-CD38 monoclonal antibodies has signific...

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress

Shenhao Liu, Chongsheng Qian, Haiping Dai et al. Nov 03, 2025 pp. 3358-3358 10.1182/blood-2025-3358

Abstract Background: Intensive, multiagent chemotherapy remains the cornerstone of conventional therapy for B-cell acute lymphoblastic leukem...

EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma

Ting-Hsiang Huang, Chih-Chao Hsu, Junfei Zhao et al. Nov 03, 2025 pp. 5699-5699 10.1182/blood-2025-5699

Abstract Background: Mezigdomide (Mezi, CC-92480) is a novel CRBN E3 ligase modulator (CELMoD) agent, that induces rapid and deep degradatio...

Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study

He-nan Wang, Xin-di Liu, Yuan-zheng Liang et al. Nov 03, 2025 pp. 3715-3715 10.1182/blood-2025-3715

Abstract Background: Although anti-CD19 CAR-T cell therapy demonstrates high response rates in Diffuse Large B-Cell Lymphoma (DLBCL), therape...

Outcomes of umbilical cord blood transplantation for acute myeloid leukemia in the era of FLT3 inhibitors.

Aya Nishida, Mika Kuno, Otoya Watanabe et al. Nov 03, 2025 pp. 7827-7827 10.1182/blood-2025-7827

Abstract Background: FLT3-mutated acute myeloid leukemia (AML) has long been associated with poor prognosis. The introduction of FLT3 inhibi...

Enhancing donor cell engraftment in prenatal hematopoietic stem cell transplantation with novel antibody-drug conjugates

Oluwaseun Babatunde, Madeleine Bibby, Walaa Mohamed et al. Nov 03, 2025 pp. 4086-4086 10.1182/blood-2025-4086

Abstract In-utero hematopoietic stem cell (HSC) transplantation (IUTx) has been safely performed in humans for decades, but clinical efficac...

GLP‑1 receptor agonists and clonal hematopoiesis: Early human signals of anti‑inflammatory clone mitigation and lower MDS‑to‑AML progression

Mark Orland, Asfand Yar Cheema, Zachary Brady et al. Nov 03, 2025 pp. 1385-1385 10.1182/blood-2025-1385

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become a near-ubiquitous consumer phenomenon for weight loss, frequently...

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Shirong Liu, Xia Liu, Amanda Kofides et al. Nov 03, 2025 pp. 2171-2171 10.1182/blood-2025-2171

Abstract Background: BTK is a key mediator of BCR signaling that promotes survival in various B-cell malignancies. Mutations in MYD88, frequ...

Preliminary clinical experience with mesenchymal stromal cells in autoimmune hemolytic anemia: A Case series in two dogs and one cat

Anezka Klubalova, Radek Klubal Nov 03, 2025 pp. 4965-4965 10.1182/blood-2025-4965

Abstract Autoimmune hemolytic anemia (AIHA) is a rare but potentially life-threatening immune-mediated disorder characterized by the destruc...

Impact of HIV status on clinical outcomes in diffuse large B-cell lymphoma and burkitt lymphoma: A national retrospective analysis

Vaishali Deenandayalan, Abul Hasan Shadali Abdul Khader, Arya Roy Nov 03, 2025 pp. 8014-8014 10.1182/blood-2025-8014

Abstract Background: Patients with Human Immunodeficiency Virus (HIV) are at increased risk for aggressive lymphomas suc...

Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Luciano Costa, Kelly Godby, Gayathri Ravi et al. Nov 03, 2025 pp. 363-363 10.1182/blood-2025-363

Abstract Introduction QUAD induction with a proteasome inhibitor, an immunomodulatory agent, anti-CD38 monoclonal antibody, and dexamethason...

Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples

Ying-Jung Huang, Ming-Chung Kuo, Tung-Liang Lin et al. Nov 03, 2025 pp. 5555-5555 10.1182/blood-2025-5555

Abstract Background and purpose:Somatic mutations in blood cancer genes have recently been investigated inchronic myeloid leukemia (CML) and...

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Sara Torres-Esquius, Maria Gabarros-Subira, Carmelo Gurnari et al. Nov 03, 2025 pp. 4997-4997 10.1182/blood-2025-4997

Abstract Introduction Germline ETV6 mutations (gETV6) are linked to mild-to-moderate thrombocytopenia, bleeding tendency and ~30% lifetime r...

Understanding the menopause transition in sickle cell disease: An analysis of the implementation of the adapted menopause quick 6

Marwah Farooqui, Santosh Saraf, Xu Zhang et al. Nov 03, 2025 pp. 4448-4448 10.1182/blood-2025-4448

Abstract Background: Women with sickle cell disease (SCD) may experience accelerated reproductive aging and premature or early menopause (be...

Facility type and survival outcomes in extranodal NK/T-cell lymphoma, nasal type: A national cancer database analysis

Gabriel Giraldo Ospino, Leyla Bojanini, Erin Kaser et al. Nov 03, 2025 pp. 8022-8022 10.1182/blood-2025-8022

Abstract Background Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) is an aggressive lymphoma associated with Epstein–Barr virus infec...

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Zhao Peiqi, Min Bai, Chen Huang et al. Nov 03, 2025 pp. 1843-1843 10.1182/blood-2025-1843

Abstract Background Elderly patients (≥60 years) with classical Hodgkin lymphoma (cHL) experience disproportionately poor outcomes, with his...

Persistent B-cell aplasia predicts late severe infections after anti-CD19 CAR T-cell treatment in B-cell lymphoma : A methodological approach to long-term safety reporting

Remi Tilmont, Maxime Delforge, Nicolas Gazeau et al. Nov 03, 2025 pp. 6297-6297 10.1182/blood-2025-6297

Abstract Introduction B-cell aplasia (BCA) is an on-target, off-tumor effect of CD19 CAR T-cells that correlates with their persistence but...

Prolonged thrombocytopenia following diverse CAR-T cell therapies: High incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort

Guoai Su, Peihao Zheng, Xuelin Han et al. Nov 03, 2025 pp. 4169-4169 10.1182/blood-2025-4169

Abstract Background: Prolonged thrombocytopenia (PT) is a major toxicity following chimeric antigen receptor (CAR) T-cell therapy, increasin...

Enhanced homing and infiltration capabilities of CI9 cells improve treatment efficacy for T-cell acute lymphoblastic leukemia with extramedullary involvement

Jinfeng Ma, Depei Wu, Nan Xu et al. Nov 03, 2025 pp. 7643-7643 10.1182/blood-2025-7643

Abstract Current CAR-T therapies targeting pan-T-cell antigens for T-cell acute lymphoblastic leukemia (T-ALL) are challenged by fratricide...

Propensity score-matched analysis supports the survival benefits of combination chimeric antigen receptor T-cell therapy with autologous transplantation in relapsed or refractory B-cell non-Hodgkin lymphoma: Insights from a real-world study in China

Kaiyu Sheng, Tao You, Qian Cheng et al. Nov 03, 2025 pp. 3725-3725 10.1182/blood-2025-3725

Abstract Background :Chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved lymphoma outcomes. However, real-world data evalu...

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Manpreet Saini, Ejaz Shah et al. Nov 03, 2025 pp. 7595-7595 10.1182/blood-2025-7595

Abstract Background: Talquetamab (Tal), a GPRC5D-targeting bispecific antibody, has emerged as a promising therapy for heavily pretreated pa...

Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy

Philip Choi, Charlotte Bradbury, Tomas Jose Gonzalez-Lopez et al. Nov 03, 2025 pp. 844-844 10.1182/blood-2025-844

Abstract Introduction Primary immune thrombocytopenia (ITP) remains an area of unmet clinical need, particularly for patients who are refrac...

The impact of patient personality traits on adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Mahtab Jafari, Alex Shahverdian, Nicole Mohajer et al. Nov 03, 2025 pp. 4638-4638 10.1182/blood-2025-4638

Abstract Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion oncoprotein and treated with oral ty...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page